6533b853fe1ef96bd12acaf9

RESEARCH PRODUCT

Femtosecond‑LASIK outcomes using the VisuMax®‑MEL® 80 platform for hyperopia and hyperopic astigmatism refractive surgery

Bogdana TăbăcaruAdrian TeodoruRuxandra PirvulescuCosmin RoșcaMihnea MunteanuC DanielescuHoria Tudor StancaSimona Stanca

subject

hyperopia0301 basic medicineCancer Researchmedicine.medical_specialtyDistance visual acuitygenetic structuresmedicine.medical_treatmentEmmetropiaKeratomileusis03 medical and health sciences0302 clinical medicineImmunology and Microbiology (miscellaneous)Refractive surgeryOphthalmologymedicineFemto-LASIKDioptrebusiness.industryLASIKArticlesGeneral Medicinehyperopic astigmatismeye diseasesfemtosecond-LASIK030104 developmental biology030220 oncology & carcinogenesisFemtosecondrefractive surgeryHyperopic astigmatismsense organsbusiness

description

The present study evaluated the efficacy, the safety and the predictability of the Femtosecond laser-assisted in situ keratomileusis (Femto-LASIK) procedure for hyperopia and hyperopic astigmatism. We retrospectively analyzed the postoperative 12-month evolution of 593 eyes with hyperopia and hyperopic astigmatism that underwent Femto-LASIK treatment. The procedure was predictable and effective. No eye lost 2 lines of corrected distance visual acuity (CDVA), demonstrating a safety profile of the procedure. Nine percent of the eyes gained at least one line of CDVA. The accuracy of the spherical equivalent after 12 months was 74% within ±1.0 diopter (D) of emmetropia. The refractive outcomes were stable during the follow-up period. There were no significant complications during the procedure. Femto-LASIK using the VisuMax®-MEL® 80 platform was demonstrated to be a suitable option to correct selected cases of hyperopia and hyperopic astigmatism. A longer follow-up period is required to better assess the refractive results and to detect any further regression.

https://doi.org/10.3892/etm.2021.9719